Celularity Inc. (NASDAQ:CELUW) Sees Large Decline in Short Interest

Celularity Inc. (NASDAQ:CELUW) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 542 shares, a drop of 84.0% from the January 15th total of 3,393 shares. Based on an average daily trading volume, of 22,573 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 22,573 shares, the days-to-cover ratio is presently 0.0 days.

Celularity Trading Down 28.7%

NASDAQ:CELUW traded down $0.00 during trading hours on Thursday, reaching $0.01. 60,406 shares of the stock were exchanged, compared to its average volume of 18,193. Celularity has a twelve month low of $0.01 and a twelve month high of $0.75. The firm has a 50 day moving average of $0.02 and a 200 day moving average of $0.03.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.

The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.